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Traumatic brain injury is an injury to the brain parenchyma resulting from external factors such as vehicular accidents,
falls, or sports injuries. Its outcome involves primary insult followed by a cascade of secondary insult, resulting in diffuse
axonal injury further causing white matter damage. Surgical intervention targets the primary damage, whereas only
few treatment alternatives are available to treat the secondary damage. Cellular therapy could be one of the
prospective therapeutic options, as it has the potential to arrest the degeneration and promote regeneration
of new cells in the brain. We conducted a pilot study on 14 cases who were administered with autologous
bone marrow mononuclear cells, intrathecally. The follow up was done at 1 week, 3 months and 6 months
after the intervention. The Functional Independence Measure scale, the SF-8 Health Survey Scoring and the
disability rating scale were used as outcome measures. These scales showed a positive shift in scores at the end
of 6 months. Improvements were observed in various symptoms, along with activities of daily living. Improvement
in PET CT scan performed before and 6 months after the intervention in 3 patients corresponded to the clinical
and functional improvements observed in these patients. The results of this study suggest that cell therapy may
promote functional recovery leading to an improved quality of life in chronic TBI. Although the results are
positive, the improvements after cell therapy are not optimal. Hence, additional multicenter, controlled studies
are required to establish cell therapy as a standard therapeutic approach.
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PET CT scanIntroduction
Traumatic brain injury (TBI) is defined as “An insult to
the brain not of the degenerative or congenital nature,
but caused by an external physical force that may pro-
duce a diminished or altered state of consciousness which
results in impairment of cognitive abilities or physical
functions” (Bunch and Jennifer 2000). It is one of the
leading causes of morbidity and mortality in the world.
It may result in temporary or permanent behavioral and/
or emotional disturbances causing functional disability.
The underlying mechanism of injury involves primary
damage occurring at the time of impact and secondary
damage which is initiated at this time but the clinical* Correspondence: poojakul28@gmail.com
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in any medium, provided the original work is ppresentation is delayed. TBI leads to alterations in cere-
bral blood flow and oxygenation, cell death and general-
ized atrophy (Prins et al. 2013).
Very few therapeutic options are currently available to
treat TBI. As the brain has a limited potential to regener-
ate the neurons, the intervention should aim at halting the
degeneration and carrying out the process of regeneration
(Horner and Gage 2000). Hence, cell therapy may be a
prospective option. In experimental models, it has been
observed that cell therapy improves the neurological func-
tional outcome in TBI (Kim et al. 2010). Transplanted
cells may replace the lost cells by proliferation and differ-
entiation. They can also stimulate the endogenous repair
by release of trophic factors (Hsu et al. 2013). To study
the benefits of cell therapy in chronic TBI, we adminis-
tered 14 patients with autologous bone marrow derived
mononuclear cells (BMMNCs), intrathecally. BMMNCs
contain a mixture of different types of progenitor cells. Itan Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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These cells were chosen as they are easily obtainable, do
not involve any ethical issues, and are immunologically
safe (Morizane et al. 2013; Parr et al. 2007). These cells,
on injection migrate to the damaged area and bring about
the repair process. They differentiate into neurons, astro-
cytes, microglial cells and oligodendrocytes (Peter and
Chen 2002).
Rationale for using cell therapy for traumatic brain injury
Over the last few years, cell therapy has acquired signifi-
cant interest as a potential treatment strategy for various
neurological disorders such as stroke, cerebral palsy,
autism, spinal cord injury, and traumatic brain injury
(Sharma et al. 2012a; Sharma et al. 2012b; Sharma et al.
2012c; Sharma et al. 2012d; Sharma et al. 2013a; Sharma
et al. 2013b; Sharma et al. 2013c; Zhang et al. 2013). A var-
iety of cell types have been explored as potential source of
transplantation for neurological disorders, including em-
bryonic cells, bone marrow stem cells, neural stem cells,
umbilical cord blood cells and induced pluripotent cells
(Ul Hassan et al. 2009; Liu et al. 2000; Muotri 2010; Zhao
et al. 2002). The underlying mechanism of cell therapy,
to promote angiogenesis, axonal remodeling, neuro-
genesis and synaptogenesis, may help reverse the path-
ology of TBI.
Materials and method
Study design and patient selection
An open label clinical study was performed to demon-
strate the effect of intrathecal autologous bone marrow
mononuclear cells in chronic traumatic brain injury. The
protocol of the study was reviewed and approved by The
Institutional Committee for Stem Cell Research and
Therapy (IC-SCRT) in accordance to the Indian Council
of Medical Research (ICMR) guidelines. Fourteen TBI
patients were selected based on the World Medical
Association Helsinki Declaration for Ethical Principles
for medical research involving human subjects (World
Medical Association 2013). A written informed consent
was obtained from the patients and their families depend-
ing on the patient’s cognitive status. The inclusion criteria
were diagnosed cases of chronic TBI and age above 1 year.
The exclusion criteria were presence of acute infections
such as HIV/HBV/HCV, malignancies, bleeding tenden-
cies, renal failure, severe liver dysfunction, severe anemia
[Hb < 8], pregnancy, lactation, any bone marrow disorder
and other acute medical conditions such as respiratory in-
fection and pyrexia.
Study protocol
The intervention included cellular therapy and neuror-
ehabilitation. Cellular therapy included intrathecal ad-
ministration of autologous bone marrow mononuclearcells and neurorehabilitation included physiotherapy, oc-
cupational therapy, speech therapy and psychological
intervention. Patient was admitted for 6 days which in-
cluded: Day 1 of pre-intervention assessment, Day 2 of
bone marrow aspiration and administration of separated
BMMNCs, Day 3 to Day 6 of multidisciplinary neuror-
ehabilitation. Patients were followed up at 3 months, 6
months and yearly thereafter.
Pre-intervention assessment
Before the intervention, every patient underwent a detailed
neuro-evaluation by medical experts. Serological, biochem-
ical and hematological tests were also performed. Func-
tional independence of all the patients was evaluated using
Functional Independence Measure (FIM). Electroenceph-
alography (EEG), Magnetic Resonance Imaging (MRI) of
brain, with Diffusion tensor imaging (DTI) and Positron
Emission Tomography- Computed Tomography (PET-
CT) brain scans were performed in all patients before the
treatment.
Bone marrow aspiration and isolation of bone marrow
mononuclear cells
Granulocyte Colony Stimulating Factor (G-CSF) injec-
tions were administered 48 hours and 24 hours prior to
the procedure as it stimulates and mobilizes the bone
marrow stem cells (Yoon et al. 2007).
Approximately 80-100 ml bone marrow was aspirated
from the anterior superior iliac crest under local anesthesia
with or without mild sedation (depending on the case sce-
nario), using the bone marrow aspiration needle. The bone
marrow was collected in heparinized tubes. Bone marrow
smears were stained with Leishman stain. Quantitative and
qualitative analysis of bone marrow was performed. MNCs
were separated by differential centrifugation. Bone marrow
dilution is done with normal saline (ratio 1:1). Centrifuga-
tion is done at 440 × g rpm for 35 minutes in a swinging
bucket rotar without brake at 20°C. MNCs are separated
as a buffy coat. They are resusupended in 1 ml of normal
saline after washing thrice with normal saline.
They were checked manually for viability using trypan
blue dye and confirmed with propidium iodide dye in
TALI (Life Technologies. Invitrogen). Average viability
was found to be 97%. CD34+ counting was also performed
by fluorescence activated cell sorting (FACS) using CD34
PE antibody.
Administration of bone marrow mononuclear cells
The separated autologous BMMNCs (body weight × 106)
were immediately injected intrathecally using an 18 G
Touhy needle and spinal needle between fourth and fifth
lumbar vertebrae under local anesthesia with or without
mild sedation (depending on the case scenario). Simultan-
eously, 20 mg/kg body weight methyl prednisolone in 500
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vival of the injected cells.
Neurorehabilitation
Every patient underwent a personalized neurorehabilita-
tion program immediately after cellular therapy and was
advised to continue as a home program. This included
physiotherapy, occupational therapy, psychological ther-
apy and speech therapy.
Follow –up and outcome measure
Patients were followed up at 1 week, 3 months and 6
months after the intervention. A complete neurological
evaluation was performed. All the outcome measures
were scored before and 6 months after the intervention.
FIM was repeated to monitor improvements in daily
functional activities. SF-8 Health Survey Scoring was
performed to assess overall health of the patients for
their quality of life. Only 7 out of 14 patients were eli-
gible for SF-8 test, due to their cognitive status. Disabil-
ity rating scale (DRS) was performed on all the patients.
Three patients chose to repeat 18-FDG PET-CT scan at
the end of 6 months to monitor the functional metabolic
changes in brain after the intervention.
Results
The study included fourteen patients with chronic TBI.
(Table 1) The median age of the study sample was 26 years
(Range: 12 years to 65 years). The patients were followed
up at 1 week, 3 months and 6 months while, 1 patient was
lost to follow up. A detailed neurological evaluation was
performed for every patient.
One week after the intervention, 5 out of 13 patients
improved in speech, 3 improved in trunk and upper limbTable 1 Demographical data




Age <20 years 5
20-30 years 4
>30 years 5
Cause of trauma RTA 7
Fall from Height 3
Train accident 3
Fall of heavy object 1
Duration since injury <5 year 8
>5 years 6
History of seizures Present 7
Absent 7
(Total Sample Size =14).activity, oromotor activities, muscle tone, voluntary con-
trol, ambulation and gait pattern and posture, 2 im-
proved in lower limb activity, balance and psychological
status, and 1 improved in cognition, memory, ADLs and
communication.
Three months after the intervention, 8 showed im-
provements in voluntary control, 7 in trunk and upper
limb activity, 6 in speech, lower limb activity and ambu-
lation and gait patterns, 5 in posture, 4 in muscle tone,
balance, ADLs, psychological status, coordination and
communication, 3 in oromotor activities and 2 in cogni-
tion and memory.
At the end of six months, a percentage analysis was car-
ried out for improvement in every symptom (Figure 1).
Amongst 13 patients, 73% showed improvement in bal-
ance, 69% in voluntary control, 60% in memory, 57% in
oromotor activities, 55% in lower limb activity and ambu-
lation and gait patterns, 54% in trunk and upper limb ac-
tivity, 50% in speech, posture and communication, 45% in
psychological status, 38% in cognition, 36% in muscle tone
and coordination and 33% in ADLs.
SF8 scale was performed on 7 patients who met the eli-
gibility criteria of the test. Six months after the interven-
tion, the mean physical component summary (PCS8)
score improved from 39.11 to 45.27 and mean mental
component summary (MCS8) from 48.44 to 52.55 (Table 2
and Figure 2). On the DRS, 6 out of 13 patients showed
reduced scores while the scores remained the same in 7
cases. It was observed that these patients showed im-
proved scores primarily in the cognitive component of
the DRS.
PET CT scans were repeated in 3 patients at the end
of six months and they showed improved metabolism
after intervention. The changes were consistent with the
clinical and functional improvements demonstrated by
these patients (Table 3).
Ten out of 14 patients had an abnormal EEG before
the intervention. Of these, 7 had a previous history of sei-
zures and were on antiepileptic medication but, only one
had an episode of seizure 3 months following intervention
but this still warrants consideration as one of the adverse
events of cell therapy.
Discussion
The pathophysiology of TBI involves primary injury which
is the immediate cause of physical or biomechanical effect
of trauma. This is followed by a cascade of secondary events
leading to excitotoxicity, increase in free radicals, cerebral
ischemia, intracranial hypertension, hypo/hyperperfusion,
impairment of cerebrovascular autoregulation and cerebral
metabolic dysfunction (Smith et al. 1997). The cascade of
events releases a number of neurochemical factors which
are responsible for cellular death. This may result in re-
gional or generalized atrophy, depending on the type and
Figure 1 Graph representing symptomatic improvements in traumatic brain injury after cell therapy.
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suggests that diffuse injury is more common than focal in-
jury and damage commonly occurs in the frontal and tem-
poral lobes, corpus callosum, basal ganglia, hypothalamus,
superior cerebellar peduncles, fornices and the hippocam-
pus (Jorge and Starkstein 2005; Schwarzbold et al. 2008).
Damage to these areas is primarily responsible for depres-
sion, mood disorders and other neurobehavioral and psy-
chiatric deficits in TBI. In TBI, the white matter tracts are
damaged due to the injury. This disrupts the cortical-
subcortical pathways, further affecting the cognition of
the patient. The greater the reduced white matter integ-
rity, the greater is the cognitive deficit (Kraus et al. 2007).
It is a challenge to repair the injured brain, due to the lim-
ited capacity of the brain to regenerate functional neurons.
Currently, no clinical treatment is available to repair the
diffuse axonal injury and reverse the pathologic cascade ofTable 2 SF8 scores before and after intervention
Patient no. SF8 pre SF8 post
PCS8 MCS8 PCS8 MCS8
1 28.4 32.5 39.2 40.8
2 44.4 52.1 51.4 59.8
3 47.1 35.4 48.6 43.2
4 33.4 51.5 43 55.9
5 39 64.1 43.1 62.7
6 43.7 58.8 50.1 58.3
7 37.8 44.7 41.5 47.2cell death and improve neurobehavioral outcome. How-
ever, cell therapy has opened up new avenues for treat-
ment strategies in various incurable neurological disorders
including TBI. Different types of cells have been explored
and amongst them bone marrow mononuclear cells are
relatively safe and easily obtainable.
Composition of bone marrow mononuclear cells
To demonstrate the effect of cell therapy on chronic TBI,
we administered autologous bone marrow mononuclear
cells in 14 patients. These cells are a heterogeneous mix-
ture of hematopoietic cells, mesenchymal cells, very small
embryonic like cells (VSELs) and endothelial progenitor
cells. It has been observed that use of BMMNCs is more
successful than the sub fractionated cell preparations
(Lawall et al. 2010).
Mechanism of action of bone marrow mononuclear cells
Cell therapy mimicks the natural repair process in TBI. In
acute TBI the endogenous stem cells are activated as a
natural process (Ahmed et al. 2014). These cells migrate
towards the site of injury and carry out the repair process.
However, the number of these activated cells are less in
the chronic phase. Therefore, in chronic phase, cell ther-
apy is a mode of increased supply of stem cells for repair.
Evidence suggests that these cells protect and repair the
damaged central nervous system via multiple mechanisms.
The transplanted cells survive and migrate towards the
damaged tissues and promote functional recovery. They
proliferate and differentiate into various cells including
Figure 2 Graph representing the mean values of pre and post physical components and mental components of SF8 health survey scoring.
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2000). In TBI, the loss of myelin disrupts the signal trans-
duction and damages the axons. The oligodendrocytes
help in remyelination of the damaged axons in the injured
brain and repair the neural connections. Bone marrow
cells also produce various growth factors and neurotrophic
factors such as brain-derived neurotrophic factor (BDNF),
nerve growth factor (NGF), vascular endothelial growth
factor (VEGF), basic fibroblast growth factor (bFGF), andTable 3 Areas of the brain showing improved metabolism in
improvement
Patient Areas of the brain showing improved metabolism in PET CT
Patient 1 Parieto-Occipital Areas












Thalamushepatocyte growth factor (HGF), which stimulate the en-
dogenous neuroprotection and repair (Zhong et al. 2003).
Route of administration
To augment the effect of these cells, it is important to ad-
minister them through an optimal route of transplant-
ation. In this study, we transplanted the cells intrathecally
as they are minimally invasive and are more targeted than
intravenous transplantation. Although direct intracerebralPET CT scan and their correlation to the clinical function
scan Functions improved
Cognition, speech, sensation, orientation and visual perception
Emotion, attention, cognition, memory
Emotional responses, memory, attention
Planning, Long term memory, emotions, speech, problem solving
Speech, memory
Emotional responses, memory, attention
Coordination, balance
Emotion, attention, cognition, memory




Planning, Long term memory, emotions, speech, problem solving
Motor control, sensory functions
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vasive procedure which could result in secondary damage.
Intravenous transplantation is also minimally invasive, but
studies have shown that when these cells are delivered
through this route they are initially trapped in the lungs
and the number of cells reaching the target tissue is ques-
tionable (Fischer et al. 2009).
Clinical outcome of this study
Our study population was followed up at 1 week, 3
months and 6 months after the intervention. We observed
significant symptomatic improvements, starting from one
week to 6 months after intervention. According to Park et
al, the immediate functional improvements observed one
week after the intervention may be due to the neuropro-
tective effects of neurotrophic factors produced by the
transplanted cells rather than integration of stem cells and
replacement of lost tissues (Park et al. 2006). Along with
major symptoms of chronic TBI shown in Figure 1, im-
provement was observed in fine motor skills of 5 patients,
attention and concentration of 3 patients, socialization skills
of 2 patients, sensation and contractures/deformities of 1
patient. In addition, 1 patient with right side facial muscle
paralysis also showed improvement after intervention.
Three patients showed an increase in FIM score, indi-
cating improvement in daily functional activities. SF8, a
health related quality of life scale, was performed on the
eligible 7 patients. It is a brief questionnaire of 8 questions
assessing physical and mental health of the affected patient.
On SF8 scale, all patients showed improvement in physical
components while 5 in mental component indicating im-
proved quality of life. On DRS, 6 out of 13 patients showed
reduced scores indicating improved functions. It was ob-
served that the patients showing reduced scores had severe
TBI while, the patients who showed no change had mild
TBI. The lack of measured improvement in the mild TBI
patients may be due to a lack of sufficient sensitivity of the
DRS instrument, given that the pre-intervention scores in
the mild TBI patients were near normal. Nonetheless,
these outcome measures suggest that cell therapy may pro-
mote functional recovery leading to an improved quality of
life in chronic TBI.
PET CT scan findings
The PET CT scans provide measures of brain glucose
metabolism using tracer [18F] fluorodeoxyglucose (FDG).
The brain glucose metabolism indirectly correlates with
the function of the neurons. Hypometabolism indicates
hypofunctionality and hence, improvement in function
will be seen as increased metabolism (FDG uptake). A
limited number of studies have been performed with
FDG-PET in TBI. Previous studies have shown decreased
metabolism in the frontal cortex, temporal cortex, thal-
amus, and cerebellum areas after TBI (Kato et al. 2007;Nakashima et al. 2007). In this study, the patients who
underwent PET CT scan 6 months post intervention
showed significant changes as shown in supplemental
table (Table 3). These changes corresponded to the symp-
tomatic improvement. The PET CT scan records the cel-
lular changes in the form of metabolism. Hence, for future
studies, PET CT scan should be considered, not only for
diagnosis, but also to monitor effect of cell therapy in TBI.
Adverse events
This study also evaluated the adverse events associated with
cell therapy. Out of 7 patients with an abnormal EEG and a
history of seizures pre-intervention, only 1 patient had an
episode of seizure within 3 months after intervention. The
episode of seizures could be due to activation of epilepto-
genic foci or abnormal innervation during neurogenesis.
Seizures, as adverse events, have been recorded earlier in
studies of stroke and autism (Sharma et al. 2013c; Lee et al.
2010), Hence its possibility in TBI cannot be eliminated.
Future detailed study will include an in-depth analysis.
Limitations and future directions
One of the major limitations of this study is that it is an
uncontrolled study with a small study population. Due to
lack of control group, we have to be judicious about dir-
ectly attributing improved scores solely to cell therapy as
rehabilitation may have also contributed to the results in
this study. There are limited number of clinical studies
demonstrating the benefits of cell therapy in traumatic
brain injury, so, this study supplements the available infor-
mation and may help to design larger, multicentre, con-
trolled studies.
Future studies should identify the ideal cells for thera-
peutic use, along with the ideal route of administration.
The optimum quantity of cells, frequency of doses and the
time interval between consecutive doses should be estab-
lished. It is important to determine the timing of cell trans-
plantation as in acute phase of injury; inflammation and
pathological metabolic changes make the endogenous
environment inhospitable for the injected cells making
their survival difficult (Morganti-Kossmann et al. 2002). In
addition, chronic effects may include gliotic changes, which
may affect the efficacy of cell therapy. Another important
area of concern is to monitor the changes in the brain and
the repair process. In this study, PET CT scan was repeated
in only 3 patients to monitor the metabolic changes in the
brain after intervention. An objective method should be
studied for this purpose. Various experiments need to be
conducted and compared to discover the precise combin-
ation that will exhibit optimal results in chronic TBI.
Conclusion
Our results suggest that cell therapy in combination with
neurorehabilitation has a potential to reverse the damage
Sharma et al. SpringerPlus  (2015) 4:26 Page 7 of 8occurred in the brain after chronic TBI. It addresses the
diffused nature of injury, which a surgical intervention
may not tackle. The resulting angiogenesis, along with en-
dogenous repair, may improve the blood flow and oxygen
supply to the injured areas of the brain, further leading to
improved functional outcome and enhanced quality of life.
As this is a pilot study, demonstrating the effect of cellular
therapy in chronic TBI, more evidence will be required in
order to establish cell therapy as a therapeutic modality.
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